// App-Quantinova.ai

142P : longitudinal exploratory analysis of prior- surgery everolimus circulating and clinical biomarkers in locally advanced and metastatic renal cell carcinoma patients (RCC)

Researchers

Presenter

  • R.Elaidi

Principal Investigators

  • D.Helley

  • L.Mauge

  • C.Badoual

  • E.Tartour

  • E.Braychenko

  • L.Albiges

  • B.Escudier

  • S.Oudard

Medical Centers

  • Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris, France

  • Biologic Haematology, Hopital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, Paris, France

  • Biologic Haematology, Hopital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, Paris, France

  • Medical oncology, ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, France

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

  • Immunothérapie et traitement antiangiogénique en pathologie cancérologique, Hopital European George Pompidou, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 14

  • Cluster of differentiation 45

  • Fms related tyrosine kinase 1

  • Interleukin 6

  • Stromal cell-derived factor 1

  • Vascular endothelial growth factor A

  • X-Ray Repair Cross Complementing 1

  • Regulatory T cells

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved